References
1. Siris ES, Bilezikian JP, Rubin MR, et al. Pins and plaster aren’t enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab 2003;88:3482–3486.
2. Kamel HK, Duthie EH. The underuse of therapy in the secondary prevention of hip fractures. Drugs Aging 2002;19:1–10.
3. Harrington JT, Broy SB, Derosa AM, et al. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum 2002;47:651–654.
4. Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture.Arch Intern Med 2002;162:2217–2222.
5. Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med1991;151:2026–2032.
6. Melton LJ, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis?J Bone Miner Res 1992;7:1005–1010.
7. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res1997;12:24–35.
8. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997;277:1140–1147.
9. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878–882.
10. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646–650.
11. Slagle MA. Medication update. South Med J 2001;94:574–578.
12. Hamdy RC. South Med J In press.
13. Holick MF. South Med J In press.
14. Tanner B. South Med J In press.
15. Kanis et al. DXA–diagnostic guidelines for preclinical evaluation and clinical trials in osteoporosis. J Bone Miner Res 1994:9:1137.
16. NOF treatment guidelines. National Osteoporosis Foundation. Physicians Guide to Prevention and Treatment of Osteoporosis 2003.
17. Bone mass act, July 1998: indications for bone mass measurement coverage. Federal Register1998;63:34320–34328.
18. Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporosis Int 2001;12:654–660.
19. Iglesias CP, Torgerson DJ, Bearne A, et al. The cost utility of bisphosphonates treatment in established osteoporosis. QJM 2002;95:305–311.
20. Leib ES, Lewiecki EM, Binkley N, et al. Official positions of the international society for clinical densitometry. South Med J 2004;97:107–110